ArticleCureus2025
A Case of Atrial Fibrillation and Rapid Ventricular Response in a 22-Year-Old Athlete With Sickle Cell Trait.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sickle cell trait (SCT) is generally regarded as a benign carrier state of sickle cell disease (SCD); however, emerging evidence indicates that it may be associated with adverse cardiovascular outcomes, including atrial fibrillation (AF). AF is uncommon among young, otherwise healthy athletes, and its occurrence in individuals with SCT is not extensively documented. We present a case involving a 22-year-old male collegiate football player with a history of SCT who presented with palpitations initiated during practice. Upon arrival, he was hemodynamically stable; nonetheless, his initial electrocardiogram (ECG) revealed atrial fibrillation with rapid ventricular response (AF RVR). Laboratory investigations were unremarkable, including a normal troponin level. The patient was administered intravenous (IV) diltiazem for rate control, and synchronized cardioversion was successfully performed to restore sinus rhythm. Short-term anticoagulation therapy with apixaban was prescribed, along with flecainide on an as-needed basis for rhythm management. The patient was subsequently referred for outpatient catheter ablation and placed on a three-month restriction from contact sports. This case underscores a rare presentation of AF RVR in a young athlete with SCT. Exertional stress may contribute to arrhythmogenesis through mechanisms such as vaso-occlusion, hypoxia, acidosis, and dehydration. Current guidelines recommend rate control, cardioversion when clinically indicated, and short-term anticoagulation in cases of new-onset AF. Catheter ablation presents a potential definitive therapeutic option for young, symptomatic individuals. Preventive measures for athletes with SCT should include adequate hydration, heat acclimatization, and education of players and coaching staff. This case highlights the importance of heightened awareness, adherence to guideline-based management, and the necessity for further research into the association between SCT and AF in young athletes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.